On June 8, the U.S. Food and Drug Administration approved a 12 month labeling supplement for Evolence, a collagen-based facial filler. The labeling reflects the results of an FDA review of additional clinical data that demonstrated safety and efficacy of EVOLENCE for a period of 12 months. EVOLENCE, collagen-based dermal filler used to correct of moderate to deep facial wrinkles and folds, is the first and only collagen dermal filler recognized to provide results through 12 months after an initial treatment. EVOLENCE, manufactured by Ortho Dermatologics, was originally introduced in the US in 2008 with a six-month duration labeling.
EVOLENCE is formulated from natural collagen to replace the body’s lost collagen, adding volume and structural support in depleted areas, to create a more naturally younger appearance. Because natural collagen is used, patients require no pre-testing. Results are immediate and visible, with minimal to no bruising or swelling.
EVOLENCE is the first and only collagen-based dermal filler recognized in the US to provide results through 12 months after an initial treatment.
Tags: collagen dermal filler, collagen injections, cosmetic dermatology, dermal filler, evolence, wrinkle injection
Leave a Reply